Virupaksha Organics Ltd.: A Leading Producer of Fexofenadine HCl
Virupaksha Organics Ltd. has solidified its position as a key player in the global pharmaceutical industry, particularly in the production of Fexofenadine Hydrochloride (HCl), a widely used antihistamine for treating allergy symptoms. With cutting-edge manufacturing facilities in Telangana, India, Virupaksha adheres to the highest international standards of quality and compliance, ensuring the production of top-quality Fexofenadine HCl for both domestic and international markets.
Virupaksha’s facilities are certified by WHO-GMP, ISO 9001, and ISO 14001, which attests to the company’s commitment to maintaining rigorous quality control and environmental management. The company’s production capabilities and advanced R&D enable it to deliver cost-effective, high-purity APIs that meet the growing global demand for Fexofenadine HCl.
With its focus on innovation, sustainability, and customer satisfaction, Virupaksha Organics continues to be a trusted partner for pharmaceutical companies worldwide. Its strategic approach to producing APIs like Fexofenadine HCl positions the company as a leader in the antihistamine market, contributing to improved healthcare outcomes for millions of patients globally.
As the demand for allergy medications rises, Virupaksha Organics remains at the forefront of API production, demonstrating excellence in pharmaceutical manufacturing and reinforcing its status as a premier producer of Fexofenadine HCl.
Other Latest News
- Market Outlook: US bond yields, dollar index, FII data key triggers for next week December 22, 2024 6:32 am Daijiworld News Mumbai, Dec 22 (IANS): The market outlook for next week will depend upon several global and domestic cues, including factors linked to the US market, and FII data, according to experts on Sunday. The US factors are — bond yields, the dollar Index, initial …
- Market Recap: A Week That Wasn't As Indices Drowned In Red December 22, 2024 6:32 am Free Press Journal Weekly Market Review Dalal Street saw its worst week in over 2 years with Nifty & the Sensex down over 4 per cent, the biggest weekly fall since June of 2022. With this the BSE-listed companies have wiped out nearly Rs 20 lakh crore in investor wealth …
- Business News | Market Ahead: Domestic Stocks May React to FIIs Flow, GST Council Decisions, IPOs for Fresh Cues December 22, 2024 5:27 am Latestly Mumbai (Maharashtra) [India], December 22 (ANI): The participants in the Indian market will be keenly monitoring foreign institutional investment (FII) flow trends, global market performance, and initial public offering activities in the domestic markets …
- Latest News | FPIs Pull out Equities Worth Rs 976 Cr This Week Amid Rising Dollar, Bond Yields December 22, 2024 5:26 am Latestly New Delhi, Dec 22 (PTI) After two weeks of buying, FPIs turned net sellers in Indian equities this week, with a net withdrawal of Rs 976 crore amid a strengthening US dollar and steady rise in US 10-year bond yields, impacting investor sentiment. Foreign …
- New-Age Tech Stocks Bleed Amid Broader Market Slump, Delhivery Biggest Loser December 22, 2024 5:08 am Inc42 SUMMARY Eighteen out of the 30 new-age tech stocks under Inc42’s coverage fell in a range 0.05% to over 10% between December 16 and 20 In the broader market, benchmark indices Sensex fell 4.98% to end the week at 78,041.59 and Nifty 50 slumped 4.76% to 23, …
- Forbes Middle East Women's Summit Kicks Off in Riyadh Bringing Together A Remarkable Cohort of Visionary Female Leaders and Global Influencers December 22, 2024 5:02 am Eye of Riyadh The second edition of Forbes Middle East’s Women’s Summit kicked off today at the Riyadh International Convention & Exhibition Center in Saudi Arabia. Celebrating the leadership and visionary achievements of women across the region, the summit serves …
- Week Ahead: F&O expiry, IPOs & listings, FII activity, global cues among key market triggers for Sensex, Nifty December 22, 2024 5:01 am Livemint The Indian stock market recorded its steepest weekly decline in almost two-and-a-half years after bears dominated bulls, dragged by weak global and domestic market cues and a sharp mid-week turn of foreign capital outflow. In the fourth week of December, …
- Year-ender 2024: FII selling crosses Rs 1 lakh crore in 2 sectors. Will 2025 see a U-turn? December 22, 2024 4:36 am The Economic Times Even as foreign investments in Indian equities remained patchy in 2024, Foreign Portfolio Investors (FPIs) were quite severe on two sectors viz. financials and oil & gas where they sold shares worth over Rs 1 lakh crore. They have been net sellers in a …
- Automating Submission Compilation and Review: The Next Challenge for Regulatory GenAI December 21, 2024 11:21 pm American Pharmaceutical Review Generative AI (GenAI) is not a theoretical game-changer in life sciences; the technology is already transforming everyday regulatory and safety processes. This is thanks to its ability to digest, assess, and summarize key insights and findings from across …
- United States v. CVS: DOJ Alleges Pharmacy Filled 'Pill Mill' Prescriptions, Billed the Government December 21, 2024 5:00 pm Red State The opinions expressed by contributors are their own and do not necessarily represent the views of RedState.com. On Wednesday, the Justice Department unsealed a civil complaint alleging that CVS Pharmacy Inc. and its subsidiaries filled “unlawful” …
- 'India Will Be World's Growth Engine': PM Addresses 'Hala Modi' Event In Kuwait December 21, 2024 3:12 pm News18 Last Updated:December 21, 2024, 20:35 IST PM Modi, the first Indian leader to visit Kuwait in 43 years, sought to highlight India's achievements in several fields like space and startup ecosystem during the 'Hala Modi' event. PM Modi addressing …
- Adaptability of it in Animal Health Pharma December 21, 2024 1:11 pm Pharma Tech Outlook Gary Fling is a trailblazer in information management and technology, with over 40 years of experience across leading organisations such as Johnson & Johnson, Endo Pharmaceuticals and Atlantic Richfield Company. His career journey began during the …
- The Era Of Agentic AI, Hyper-Personalisation & More: GenAI Predictions For 2025 December 21, 2024 1:04 pm Inc42 By the end of 2023, the generative AI (GenAI) fever was deemed to be more than just a fad. And 2024 perhaps established the same with many calling it bigger than the internet itself. But what’s in store for GenAI in 2025? Despite oscillating between …
- GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227 gets EMA PRIME designation in relapsed extensive-stage small-cell lung cancer December 21, 2024 12:26 pm Pharmabiz.com GSK plc, a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together, announced that the European Medicines Agency has granted Priority Medicines (PRIME) Designation for GSK’227, its B7-H3-targeted …
- NPPA Fixes Retail Price of 65 New Drugs, Ceiling Price of 20 Formulations, Details December 21, 2024 11:28 am Medical Dialogues New Delhi: Through recent notifications, the National Pharmaceutical Pricing Authority (NPPA), under the Ministry of Chemicals and Fertilizers, has fixed the maximum retail price of 65 new drugs, along with determining the ceiling price for 13 scheduled …
- FPIs log Rs 21,789 crore inflows in December so far, reversing months of outflows December 21, 2024 11:22 am The Economic Times Foreign portfolio investors (FPIs) recorded net equity inflows of Rs 21,789 crore in December so far, marking a significant reversal after months of heavy outflows. With this surge in December, FPIs have experienced a total net inflow of Rs 6,770 crore in …
- 2025: A tale of two halves; ICICI Bank, Zomato among Motilal Oswal’s top 10 picks December 21, 2024 10:43 am The Economic Times After an eventful 2024 with Nifty delivering 13% returns on a year-to-date basis, 2025 could be a tale of two halves according to Motilal Oswal Financial Services, which sees consolidation in the first six months while a recovery in the next. The brokerage …
- SkyCell invests millions in Validade, becomes major shareholder December 21, 2024 10:04 am STAT Trade Times SkyCell, a global leader in safe and sustainable pharma supply chain solutions, announced a multimillion investment to become a major shareholder in Validaide, the Netherlands-based digital platform for pharma lane risk management and collaboration. " …
- Senores Pharma IPO: GMP, subscription status to review. Apply or not as the issue gets fully booked on day one? December 21, 2024 9:42 am Livemint Senores Pharma IPO: Bidding for the initial public offering (IPO) of Senores Pharma Limited began on 20th December 2024 and will remain until 5:00 PM on 24 December 2024. So, applicants have two days to apply for the Senores Pharma IPO as the public issue …
- AIPAC kicks off landmark Pharma MSME programme in Indore with overwhelming response December 21, 2024 4:18 am Pharmabiz.com The All India Pharmaceutical Associations Consortium (AIPAC) recently unveiled its maiden initiative for Micro, Small, and Medium Enterprises (MSMEs) in the pharmaceutical sector at the Prestige Institute of Management and Research, Indore. The event, with …
- Pharma Fridays — December 20, 2024 December 20, 2024 8:10 pm Endocrine News An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism Corcept …
- How Adragos is building a more resilient pharma supply chain December 20, 2024 7:07 pm European Pharmaceutical Manufacturer The global pharmaceutical industry is facing unprecedented supply chain challenges in the current climate of geopolitical uncertainty. Marco Gorgas, chief technical officer, Adragos Pharma explains. The intricate network of manufacturing, sourcing, and …
- Fierce Pharma Asia—Merck's oral GLP-1 play; Astellas' gene therapy deal; Betta's FDA nod December 20, 2024 3:29 pm Fierce Pharma Merck in-licensed a preclinical oral GLP-1 candidate from China's Hansoh Pharma. Astellas doubled down in gene therapy with a viral capsid deal with Sangamo Therapeutics. Betta Pharma's Ensacove became the first innovative targeted lung cancer med …
- Sensex, Nifty extend losses amid weak global cues December 20, 2024 3:28 pm India Today Benchmark indices on Dalal Street continued their losing streak on Friday, tracking declines in Asian markets after the US Federal Reserve projected fewer interest rate cuts next year. At 10:28 am, the S&P BSE Sensex fell 274.86 points to 78,943.19, …
- Setback for UK pharma as government sets unexpectedly high VPAG payback rate in 2025 December 20, 2024 3:08 pm Pharmaceutical Technology The UK Department of Health and Social Care (DHSC) has announced its anticipated 2025 headline payback rate for new medicines under the 2024–2028 Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG). VPAG operates as the current form of …